A Phase 2, Randomized, Dose-escalation, Observation-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of RGX-314 Gene Therapy Delivered via a Single Suprachoroidal Space (SCS) Injection in Participants with Diabetic Retinopathy (DR) Without Center Involved-Diabetic Macular Edema (CI-DME).
Cystoid Macular Edema after Cataract Surgery (Allergan)
Phase 2 Study of the Dexamethasone Intravitreal Implant (Ozurdex) for combined Pseudophakic Cystoid Edema and Diabetic Macular Edema after cataract surgery.
DA VINCI (Regeneron)
Phase 2 study of the safety, tolerability and biological effect of repeated aflibercept (Eylea) in diabetic macular edema.
Phase 2 study of the efficacy and safety of PF-04523655 versus laser in diabetic macular edema.
PACIFIC (Allegro)A 6 month, phase 2, randomized, double-masked, placebo-controlled multicenter clinical trial designed to evaluate the safety and efficacy of Luminate in inducing PVD in subjects with non-proliferative diabetic retinopathy.
PANORAMA (Regeneron)A 2 year, Phase 3, multicenter, randomized study of the efficacy and safety of intravitreal aflibercept (Eylea) injection in patients with moderately severe to severe nonproliferative diabetic retinopathy.
Phase 3 study of the efficacy and safety of Ranibizumab (Lucentis) in diabetic macular edema.
A 3 year Phase 3 study of the efficacy, safety and tolerability of aflibercept (Eylea) in patients with diabetic macular edema.